Use of omic technologies in early life gastrointestinal health and disease: from bench to bedside

Expert Rev Proteomics. 2021 Apr;18(4):247-259. doi: 10.1080/14789450.2021.1922278. Epub 2021 May 2.

Abstract

Introduction: At birth, the gastrointestinal (GI) tract is colonized by a complex community of microorganisms, forming the basis of the gut microbiome. The gut microbiome plays a fundamental role in host health, disorders of which can lead to an array of GI diseases, both short and long term. Pediatric GI diseases are responsible for significant morbidity and mortality, but many remain poorly understood. Recent advancements in high-throughput technologies have enabled deeper profiling of GI morbidities. Technologies, such as metagenomics, transcriptomics, proteomics and metabolomics, have already been used to identify associations with specific pathologies, and highlight an exciting area of research. However, since these diseases are often complex and multifactorial by nature, reliance on a single experimental approach may not capture the true biological complexity. Therefore, multi-omics aims to integrate singular omic data to further enhance our understanding of disease.Areas covered: This review will discuss and provide an overview of the main omic technologies that are used to study complex GI pathologies in early life.Expert opinion: Multi-omic technologies can help to unravel the complexities of several diseases during early life, aiding in biomarker discovery and enabling the development of novel therapeutics and augment predictive models.

Keywords: Biomarker; gut microbiome; inflammatory bowel disease; metabolomics; metagenomics; necrotizing enterocolitis; omics; proteomics; sepsis; transcriptomics.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Child
  • Gastrointestinal Microbiome*
  • Gastrointestinal Tract
  • Humans
  • Infant, Newborn
  • Metabolomics
  • Metagenomics*
  • Proteomics